Fabienne Lucas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fabienne Lucas has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Catherine J. Wu
Dana-Farber Cancer Institute
15 shared publications - Donna Neuberg
Department of Data Science, Dana-Farber Cancer Institute, Boston, USA
15 shared publications - Mohamed Uduman
Victory Genomics, Inc , Guilford, CT
15 shared publications - Alanna Sholokhova
13Department of Applied Mathematics, University of Washington, Seattle, Washington
9 shared publications - Binyamin A. Knisbacher
Broad Institute of MIT and Harvard, Cambridge, USA
9 shared publications - Daniel Ruben Carrasco
Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
9 shared publications
Latest Publications
- 22 April 2026
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (5) , 1236-1239
Troubleshooting Bacterial Contamination in a Diagnostic Flow Cytometry Laboratory: A Root Cause Analysis
- 22 April 2026
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (5) , 1236-1239
Troubleshooting Bacterial Contamination in a Diagnostic Flow Cytometry Laboratory: A Root Cause Analysis
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary file contains all supplementary tables S1-S16 in Excel format in the order in which they appear in the text.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary file contains all supplementary tables S1-S16 in Excel format in the order in which they appear in the text.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary file contains a PDF version of supplementary figures S1-S7 and associated figure legends.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary file contains a PDF version of supplementary figures S1-S7 and associated figure legends.
- 11 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (802) , eadq2162
DeepHeme, a high-performance, generalizable deep ensemble for bone marrow morphometry and hematologic diagnosis
Cytomorphological analysis of the bone marrow aspirate (BMA) is pivotal for the diagnostic workup of a broad range of hematological disorders. However, this skill is error prone, highly complex, and time consuming. Deep learning–based models for the automatic classification of bone marrow cell morphology demonstrate the potential to improve diagnostic efficiency and accuracy. However, existing deep learning approaches in this field fall short of expert-level performance and lack generalizability beyond a single dataset. Working with multiple hematopathologists, we curated a dataset from the University of California, San Francisco, which included a training set of 30,394 images from 40 patients with morphologically normal marrows and a test set of 8507 images from 10 different patients, all derived from 400×-equivalent whole-slide images (WSIs). We then developed DeepHeme, a snapshot ensemble deep learning classifier, which outperformed previous models in accuracy while expanding the total number of differentiable cell classes. We externally validated DeepHeme using an independent dataset from the Memorial Sloan Kettering Cancer Center, which included 2694 images from 10 morphologically normal patients and 11,076 images from 655 patients with normal or diseased marrow, scanned using a different WSI system, demonstrating robust generalizability. At the level of individual cell classifications, we systematically compared DeepHeme’s diagnostic performance with that of three medical experts from different academic hospitals, demonstrating that DeepHeme achieved accuracy comparable to, or exceeding, that of human experts. Accurate and generalizable cell classification represents a step toward automated analysis of hematopathology slides and the development of quantitative, morphology-based, predictive markers.
- 11 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (802) , eadq2162
DeepHeme, a high-performance, generalizable deep ensemble for bone marrow morphometry and hematologic diagnosis
Cytomorphological analysis of the bone marrow aspirate (BMA) is pivotal for the diagnostic workup of a broad range of hematological disorders. However, this skill is error prone, highly complex, and time consuming. Deep learning–based models for the automatic classification of bone marrow cell morphology demonstrate the potential to improve diagnostic efficiency and accuracy. However, existing deep learning approaches in this field fall short of expert-level performance and lack generalizability beyond a single dataset. Working with multiple hematopathologists, we curated a dataset from the University of California, San Francisco, which included a training set of 30,394 images from 40 patients with morphologically normal marrows and a test set of 8507 images from 10 different patients, all derived from 400×-equivalent whole-slide images (WSIs). We then developed DeepHeme, a snapshot ensemble deep learning classifier, which outperformed previous models in accuracy while expanding the total number of differentiable cell classes. We externally validated DeepHeme using an independent dataset from the Memorial Sloan Kettering Cancer Center, which included 2694 images from 10 morphologically normal patients and 11,076 images from 655 patients with normal or diseased marrow, scanned using a different WSI system, demonstrating robust generalizability. At the level of individual cell classifications, we systematically compared DeepHeme’s diagnostic performance with that of three medical experts from different academic hospitals, demonstrating that DeepHeme achieved accuracy comparable to, or exceeding, that of human experts. Accurate and generalizable cell classification represents a step toward automated analysis of hematopathology slides and the development of quantitative, morphology-based, predictive markers.
- 23 February 2024
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 106 (4) , 294-307
Translating the regulatory landscape of medical devices to create fit‐for‐purpose artificial intelligence (AI) cytometry solutions
The implementation of medical software and artificial intelligence (AI) algorithms into routine clinical cytometry diagnostic practice requires a thorough understanding of regulatory requirements and challenges throughout the cytometry software product lifecycle. To provide cytometry software developers, computational scientists, researchers, industry professionals, and diagnostic physicians/pathologists with an introduction to European Union (EU) and United States (US) regulatory frameworks. Informed by community feedback and needs assessment established during two international cytometry workshops, this article provides an overview of regulatory landscapes as they pertain to the application of AI, AI‐enabled medical devices, and Software as a Medical Device in diagnostic flow cytometry. Evolving regulatory frameworks are discussed, and specific examples regarding cytometry instruments, analysis software and clinical flow cytometry in‐vitro diagnostic assays are provided. An important consideration for cytometry software development is the modular approach. As such, modules can be segregated and treated as independent components based on the medical purpose and risk and become subjected to a range of context‐dependent compliance and regulatory requirements throughout their life cycle. Knowledge of regulatory and compliance requirements enhances the communication and collaboration between developers, researchers, end‐users and regulators. This connection is essential to translate scientific innovation into diagnostic practice and to continue to shape the development and revision of new policies, standards, and approaches.
- 23 February 2024
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 106 (4) , 294-307
Translating the regulatory landscape of medical devices to create fit‐for‐purpose artificial intelligence (AI) cytometry solutions
The implementation of medical software and artificial intelligence (AI) algorithms into routine clinical cytometry diagnostic practice requires a thorough understanding of regulatory requirements and challenges throughout the cytometry software product lifecycle. To provide cytometry software developers, computational scientists, researchers, industry professionals, and diagnostic physicians/pathologists with an introduction to European Union (EU) and United States (US) regulatory frameworks. Informed by community feedback and needs assessment established during two international cytometry workshops, this article provides an overview of regulatory landscapes as they pertain to the application of AI, AI‐enabled medical devices, and Software as a Medical Device in diagnostic flow cytometry. Evolving regulatory frameworks are discussed, and specific examples regarding cytometry instruments, analysis software and clinical flow cytometry in‐vitro diagnostic assays are provided. An important consideration for cytometry software development is the modular approach. As such, modules can be segregated and treated as independent components based on the medical purpose and risk and become subjected to a range of context‐dependent compliance and regulatory requirements throughout their life cycle. Knowledge of regulatory and compliance requirements enhances the communication and collaboration between developers, researchers, end‐users and regulators. This connection is essential to translate scientific innovation into diagnostic practice and to continue to shape the development and revision of new policies, standards, and approaches.
- 7 August 2023
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 160 (6) , 571-584
One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations
Objectives: Quantification of direct oral anticoagulant (DOAC) plasma levels can guide clinical management, but insight into clinical scenarios surrounding DOAC-calibrated anti-FXa assays is limited. Methods: Apixaban- and rivaroxaban-calibrated chromogenic anti-Xa assays performed over a 1-year period were retrospectively analyzed. Patient demographics, DOAC history, concomitant medications, and renal/liver comorbidities were obtained. Indications for testing and associated clinical actions were reviewed. Machine learning (ML) models predicting clinical actions were evaluated. Results: In total, 371 anti-FXa apixaban and 89 anti-FXa rivaroxaban tests were performed for 259 and 67 patients in recurring urgent (acute bleeding, unplanned procedures) and nonurgent situations, including several scenarios not captured by existing testing recommendations (eg, drug monitoring, recurrent thromboembolic events, bleeding tendency). In urgent settings, andexanet reversal was guided by radiologic and clinical findings over DOAC levels in 14 of 32 instances, while 51% of apixaban patients qualified for nonreversal strategies through the availability of levels. Levels also informed procedure/intervention timing and supported management decisions when DOAC clearance or DOAC target levels were in question. The importance of clinical context was emphasized by exploratory ML models predicting particular clinical actions. Conclusions: Although clinical situations are complex, DOAC testing facilitates clinical decision-making, including reversal, justifying more widespread implementation of these assays.
- 7 August 2023
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 160 (6) , 571-584
One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations
Objectives: Quantification of direct oral anticoagulant (DOAC) plasma levels can guide clinical management, but insight into clinical scenarios surrounding DOAC-calibrated anti-FXa assays is limited. Methods: Apixaban- and rivaroxaban-calibrated chromogenic anti-Xa assays performed over a 1-year period were retrospectively analyzed. Patient demographics, DOAC history, concomitant medications, and renal/liver comorbidities were obtained. Indications for testing and associated clinical actions were reviewed. Machine learning (ML) models predicting clinical actions were evaluated. Results: In total, 371 anti-FXa apixaban and 89 anti-FXa rivaroxaban tests were performed for 259 and 67 patients in recurring urgent (acute bleeding, unplanned procedures) and nonurgent situations, including several scenarios not captured by existing testing recommendations (eg, drug monitoring, recurrent thromboembolic events, bleeding tendency). In urgent settings, andexanet reversal was guided by radiologic and clinical findings over DOAC levels in 14 of 32 instances, while 51% of apixaban patients qualified for nonreversal strategies through the availability of levels. Levels also informed procedure/intervention timing and supported management decisions when DOAC clearance or DOAC target levels were in question. The importance of clinical context was emphasized by exploratory ML models predicting particular clinical actions. Conclusions: Although clinical situations are complex, DOAC testing facilitates clinical decision-making, including reversal, justifying more widespread implementation of these assays.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary file contains all supplementary tables S1-S16 in Excel format in the order in which they appear in the text.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary file contains all supplementary tables S1-S16 in Excel format in the order in which they appear in the text.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary file contains a PDF version of supplementary figures S1-S7 and associated figure legends.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary file contains a PDF version of supplementary figures S1-S7 and associated figure legends.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Transformation to aggressive disease histologies generates formidable clinical challenges across cancers, but biological insights remain few. We modeled the genetic heterogeneity of chronic lymphocytic leukemia (CLL) through multiplexed in vivo CRISPR-Cas9 B-cell editing of recurrent CLL loss-of-function drivers in mice and recapitulated the process of transformation from indolent CLL into large cell lymphoma [i.e., Richter syndrome (RS)]. Evolutionary trajectories of 64 mice carrying diverse combinatorial gene assortments revealed coselection of mutations in Trp53, Mga, and Chd2 and the dual impact of clonal Mga/Chd2 mutations on E2F/MYC and interferon signaling dysregulation. Comparative human and murine RS analyses demonstrated tonic PI3K signaling as a key feature of transformed disease, with constitutive activation of the AKT and S6 kinases, downmodulation of the PTEN phosphatase, and convergent activation of MYC/PI3K transcriptional programs underlying enhanced sensitivity to MYC/mTOR/PI3K inhibition. This robust experimental system presents a unique framework to study lymphoid biology and therapy.Significance:Mouse models reflective of the genetic complexity and heterogeneity of human tumors remain few, including those able to recapitulate transformation to aggressive disease histologies. Herein, we model CLL transformation into RS through multiplexed in vivo gene editing, providing key insight into the pathophysiology and therapeutic vulnerabilities of transformed disease.This article is highlighted in the In This Issue feature, p. 101
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Transformation to aggressive disease histologies generates formidable clinical challenges across cancers, but biological insights remain few. We modeled the genetic heterogeneity of chronic lymphocytic leukemia (CLL) through multiplexed in vivo CRISPR-Cas9 B-cell editing of recurrent CLL loss-of-function drivers in mice and recapitulated the process of transformation from indolent CLL into large cell lymphoma [i.e., Richter syndrome (RS)]. Evolutionary trajectories of 64 mice carrying diverse combinatorial gene assortments revealed coselection of mutations in Trp53, Mga, and Chd2 and the dual impact of clonal Mga/Chd2 mutations on E2F/MYC and interferon signaling dysregulation. Comparative human and murine RS analyses demonstrated tonic PI3K signaling as a key feature of transformed disease, with constitutive activation of the AKT and S6 kinases, downmodulation of the PTEN phosphatase, and convergent activation of MYC/PI3K transcriptional programs underlying enhanced sensitivity to MYC/mTOR/PI3K inhibition. This robust experimental system presents a unique framework to study lymphoid biology and therapy.Significance:Mouse models reflective of the genetic complexity and heterogeneity of human tumors remain few, including those able to recapitulate transformation to aggressive disease histologies. Herein, we model CLL transformation into RS through multiplexed in vivo gene editing, providing key insight into the pathophysiology and therapeutic vulnerabilities of transformed disease.This article is highlighted in the In This Issue feature, p. 101
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary file contains a PDF version of supplementary figures S1-S7 and associated figure legends.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Supplementary file contains a PDF version of supplementary figures S1-S7 and associated figure legends.